
Reflecting on President Trump’s first 100 days in office
Calvin Ding
Partner Litigation, Arbitration, and Employment
Languages
English, Mandarin
In the investigations space, Calvin has represented companies and their board committees in matters ranging from corruption and conflicts of interest, to trade compliance and cybersecurity incidents. These investigations span industries, and include work for market leaders in the life sciences, technology and telecommunications, chemicals, automotive, diversified industrials and retail sectors.
To help clients avoid problems, Calvin regularly advises on the design and implementation of comprehensive anti-corruption compliance programs, as well as providing guidance on pre-acquisition due diligence, risk assessments, and remediation. Having spent several years working on the day-to-day implementation of an FCPA compliance program in China to address what was then the largest FCPA case brought by the U.S. Government, Calvin has developed a keen understanding and anticipation for the ways the U.S. Government evaluates official corruption issues and the steps a company takes to forestall and address such problems. In addition, Calvin has served as a member of the anti-corruption compliance monitor team for a global medical device company during a 3-year resolution related to a World Bank Group investigation and is co-lead of the Hogan Lovells global Life Sciences sector group.
Advising a multinational information services company in investigating and responding to a ransomware attack.
Advising a Chinese telecommunications company in relation to U.S. trade sanctions and the internal investigations stemming from such sanctions.
Advised an MNC in an internal investigation stemming from allegations of conflicts of interests, improper transfer of value to employees of Chinese SOEs and manipulation of vendor selection processes.
Assisting a multinational company in managing an investigation conducted by Chinese government authorities relating to allegations of commercial bribery.
Conducted risk assessments on behalf of multiple MNCs doing business in China to assess the effectiveness of existing controls and to appraise the need for further control enhancements.
Conducting multiple investigations in the life sciences industry relating to allegations of improper sales incentives, channel stuffing, fraudulent expenses, off-label use, and drug re-sale.
Conducting due diligence for an international conglomerate involving entities in multiple jurisdictions, and advising on pre and post-closing actions relating to FCPA and Chinese anti-bribery laws.
Implementing an anti-corruption compliance program in China to address one of the largest FCPA investigations brought to date by the U.S. Government.*
Evaluating an international medical device manufacturer’s anti-corruption compliance programs and advising the company and an international financial institution on the adequacy of those programs.*
Establishing the Greater China anti-corruption compliance function of one of the largest hotel chains in the world with over 150 properties in China, Taiwan, Hong Kong, and Macau.*
Acting as compliance monitor to an international medical device manufacturer to advise the company and a multilateral development bank on the contours and adequacy of anti-corruption programs.*
Representing the audit committee of a listed company in an internal investigation with respect to conflict of interest, breach of fiduciary duty, and FCPA issues arising out of whistleblower claims.*
Represented the audit committee of a listed company in an internal investigation conducted in response to media reports alleging breach of fiduciary duties and corruption.*
*Matter handled prior to joining Hogan Lovells.